Granzyme B targeting complex, radiopharmaceutical and preparation method and application of granzyme B targeting complex and radiopharmaceutical

A technology for radiopharmaceuticals and complexes, applied in the field of nuclear medicine, can solve the problems of low tumor immunotherapy efficiency, lack of tumor specificity, and less than 30% effective rate, and achieve optimal pharmacokinetic properties and in vivo metabolic stability. , prepare a simple effect

Active Publication Date: 2022-02-11
PEKING UNIV
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current effective rate of tumor immunotherapy is low
Taking anti-PD-1 immune checkpoint inhibition as an example, its effective rate is often less than 30%
However, 18 F-FDG lacks tumor-specific, specific markers of active cells other than CTL or NK
It has obvious limitations in predicting and evaluating the efficacy of immunotherapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Granzyme B targeting complex, radiopharmaceutical and preparation method and application of granzyme B targeting complex and radiopharmaceutical
  • Granzyme B targeting complex, radiopharmaceutical and preparation method and application of granzyme B targeting complex and radiopharmaceutical
  • Granzyme B targeting complex, radiopharmaceutical and preparation method and application of granzyme B targeting complex and radiopharmaceutical

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Synthesis of granzyme B targeting complexes.

[0064] The granzyme B targeting complex (compound 7) was synthesized according to the following solid-phase synthesis route. Wherein, R is any one of bifunctional chelating groups or derivatives thereof for radionuclide labeling. The bifunctional chelating group is a group formed by bifunctional chelating agents DOTA, NOTA, HYNIC, and MAG2.

[0065]

[0066] Concrete synthetic steps are as follows:

[0067] Reaction conditions: (a) DCM solution of Fmoc-NHS and DIPEA; (b) DMF / DCM solution of 2-chlorotriphenyl chloride resin and DIPEA; (c) DMF solution of 20% piperidine, Fmoc-(2S, 5S) DMF solution of -5-amino-1,2,4,5,6,7-hexahydroazepino[3,2,1-Hi]indole-4-one-2-carboxylic acid, HBTU, HOBt and DIPEA;( d) DMF solution of 20% piperidine, DMF solution of Fmoc-L-isoleucine, HBTU, HOBt and DIPEA; (e) DMF solution of 20% piperidine, Fmoc-(3-aminomethylphenyl) The DMF solution of acetic acid, HBTU, HOBt and EIPEA; (f) the DMF ...

Embodiment 2

[0075] Synthesis of DOTA coupling complex and its 68 Ga, 64 Cu, 111 In, 86 The labeling of any radionuclide in Y is prepared into corresponding radiopharmaceuticals. Specifically include the following steps:

[0076] Take 5 μmol of compound 6, dissolve it in 500 μL of DMSO, and then add 50 μmol of DOTA-NHS and 10 μmol of DIPEA. Mix well and react at room temperature for 2 hours. The crude product is purified by HPLC and freeze-dried to obtain the DOTA-coupled granzyme B targeting complex. For its mass spectrometric characterization, see figure 1 .

[0077] Dissolve 10nmol of DOTA coupling complex in 300μL of 0.1M sodium acetate buffer (pH=5.5); then add 185MBq of 68 GaCl 3 , 64 CuCl 2 , 111 InCl 3 or 86 YCl 3 , reacted at 37°C for 30min, then, the reaction solution was separated and purified by Sep-PakC18 chromatographic column, the purified product was diluted with normal saline and then sterile filtered to obtain the corresponding 68 Ga, 64 Cu, 111 In or 86...

Embodiment 3

[0079] Synthesis of NOTA coupling complex and its 68 Ga, 64 Cu or 18 F Labeling of any radionuclide to prepare corresponding radiopharmaceuticals. Specifically include the following steps:

[0080] Take 5 μmol of compound 6, dissolve it in 500 μL of DSMO, then add 50 μmol of NOTA-NHS, and 10 μmol of DIPEA. Mixed and reacted at room temperature for 2 hours, the crude product was purified by HPLC and freeze-dried to obtain the NOTA-coupled granzyme B targeting complex. For its mass spectrometric characterization, see image 3 .

[0081] 68 Ga or 64 Cu radiolabeling: Dissolve 10nmol of NOTA coupling complex in 300μL of 0.1M sodium acetate buffer (pH=5.5); then add 185MBq of 68 GaCl 3 or 64 CuCl 2 , reacted at 37°C for 15 minutes, and after cooling, the reaction solution was separated and purified by Sep-Pak C18 chromatographic column, and the purified product was diluted with normal saline and filtered aseptically to obtain the corresponding 68 Ga or 64 Cu-labeled co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of nuclear medicine, and relates to a granzyme B targeting complex, a radiopharmaceutical and a preparation method and application of the granzyme B targeting complex and the radiopharmaceutical. The structure of the granzyme B targeting complex is shown as a formula (I), wherein R is any one of a difunctional chelating group for radionuclide labeling or a derivative thereof. The granzyme B targeting complex provided by the invention can be labeled by radionuclide to prepare a granzyme B targeting radiopharmaceutical; wherein the granzyme B targeting radiopharmaceutical provided by the invention is simple to prepare, and has better pharmacokinetic characteristics and in-vivo metabolism stability compared with other granzyme B targeting drugs; and therefore, the expression level of granzyme B in body can be noninvasively monitored through nuclear medicine imaging.

Description

technical field [0001] The invention belongs to the field of nuclear medicine, and in particular relates to a granzyme B targeting complex and a preparation method thereof, a granzyme B targeting radiopharmaceutical and a preparation method thereof, and their application in nuclear medicine imaging diagnosis and treatment of related diseases such as tumors. Applications in therapeutic imaging monitoring. Background technique [0002] Granzyme is a kind of serine protease. Human granzyme includes five kinds of A, B, H, K, and M, which exist in cytotoxic T lymphocytes (cytotoxic T lymphocytes, CTL) and natural killer cells (natural killer cells, NK). released cell granules. As one of the most important effector molecules of granzyme, granzyme B can enter cells, mediate the activation of downstream caspase signaling pathway, induce cellular DNA fragmentation, and thus lead to cell apoptosis. At the same time, granzyme B can also cut nuclear proteins, including NuMA and P and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K51/04A61K47/54A61K38/48A61P35/00A61P37/02C07K5/083C07K1/04C07K1/107C07K1/13C07K1/20
CPCA61K51/0482A61K47/547A61K38/482A61P35/00A61P37/02C07K5/0808
Inventor 刘昭飞杨兴王琰璞徐红闯周昊毅
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap